Dr. Antoni Ribas on the Search for Immunotherapy Biomarkers in Melanoma

Antoni Ribas, MD, PhD
Published: Wednesday, Sep 21, 2016


Antoni Ribas, MD, PhD, a professor of medicine, surgery, and molecular and medical pharmacology at the University of California, discusses selecting patients for immunotherapeutic agents in melanoma.  
 
Right now, besides PD-L1, there are limited biomarkers available to select patients, says Ribas.
 
To better understand potential biomarkers, there must first be a better understanding of the presence of immune cells in the tumor and of the T-cells that are triggering PD-L1 expression, says Ribas. There will also have to be an understanding of what those T-cells are, says Ribas.
 
It will also have to be determined if T-cells are recognizing tumor antigens, and if the tumor is something the immune system can recognize because it has high mutational loads and has a certain genetic profile that is permissive to an immune system, says RIbas.
 

Antoni Ribas, MD, PhD, a professor of medicine, surgery, and molecular and medical pharmacology at the University of California, discusses selecting patients for immunotherapeutic agents in melanoma.  
 
Right now, besides PD-L1, there are limited biomarkers available to select patients, says Ribas.
 
To better understand potential biomarkers, there must first be a better understanding of the presence of immune cells in the tumor and of the T-cells that are triggering PD-L1 expression, says Ribas. There will also have to be an understanding of what those T-cells are, says Ribas.
 
It will also have to be determined if T-cells are recognizing tumor antigens, and if the tumor is something the immune system can recognize because it has high mutational loads and has a certain genetic profile that is permissive to an immune system, says RIbas.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x